AiCuris Anti-infective Cures AG (AiCuris) is a German biopharmaceutical company based in Wuppertal focused on the discovery and development of anti-infective therapies. The company concentrates on innovative antivirals targeting herpesviruses and other opportunistic infections, aiming to address high unmet medical needs in immunocompromised patients, including transplant recipients.
AiCuris is known for discovering letermovir (marketed as Prevymis for cytomegalovirus prophylaxis), which it out-licensed for global commercialization. Its pipeline includes clinical-stage candidates such as pritelivir, a helicase–primase inhibitor for difficult-to-treat herpes simplex virus infections. Operating as an Aktiengesellschaft, AiCuris leverages deep virology expertise and translational development to advance new treatment options through internal R&D and collaborations.
None yet. When a new project in the record names Aicuris as owner, partner or investor, it shows here.
First patient dosed in a randomized Phase 2a trial of AIC468, an antisense oligonucleotide targeting BK virus in adult kidney transplant recipients.
Brings acquired specialty-pharma units into a single global management to pursue niche immunology, nephrology, transplant and infectious disease markets; targets ¥300bn by FY2030.
Streamline Mizushima Works by FY2030; no immediate supply impact. Exiting low-margin derivative businesses (¥116.2bn 2025) to boost margins, free capital for pharma, healthcare, homes, electronics.
Acquisition adds three antiviral assets - royalties from Prevymis, pritelivir (FDA Priority Review; PDUFA Q4 2026) and AIC468 - aims $500M revenue by 2030 and transplant/infectious-disease growth.
The acquisition enhances Asahi Kasei's pharmaceutical platform in severe infectious diseases, leveraging existing infrastructure for growth and expanding its treatment portfolio.
